genXone (GX1) Stock Overview
Operates as a biotechnology company that offers nucleic acid sequencing services based on nanopore sequencing technology in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GX1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
genXone S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł5.90 |
| 52 Week High | zł6.96 |
| 52 Week Low | zł3.81 |
| Beta | -0.36 |
| 1 Month Change | -8.95% |
| 3 Month Change | -1.67% |
| 1 Year Change | 2.79% |
| 3 Year Change | -40.40% |
| 5 Year Change | -76.40% |
| Change since IPO | -86.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| GX1 | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 0.3% | -0.4% | 3.1% |
| 1Y | 2.8% | -10.4% | 27.8% |
Return vs Industry: GX1 exceeded the Polish Biotechs industry which returned -10.1% over the past year.
Return vs Market: GX1 underperformed the Polish Market which returned 26.3% over the past year.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 5.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 11.0% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: GX1 has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: GX1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 17 | Michal Kaszuba | genxone.eu |
genXone S.A. operates as a biotechnology company that offers nucleic acid sequencing services based on nanopore sequencing technology in Poland and internationally. The company operates in the field of molecular genetics and bioinformatics. It also develops solutions in the form of laboratory protocols, as well as bioinformatics tools, scripts, and algorithms enabling the use of nanopore sequencing in various areas of science and business, including genetic diagnostics, food industry, veterinary medicine, and agriculture.
genXone S.A. Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market cap | zł19.50m |
| Earnings (TTM) | -zł2.14m |
| Revenue (TTM) | zł2.34m |
Is GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | zł2.34m |
| Cost of Revenue | zł1.05m |
| Gross Profit | zł1.29m |
| Other Expenses | zł3.43m |
| Earnings | -zł2.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 12, 2026
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 55.06% |
| Net Profit Margin | -91.50% |
| Debt/Equity Ratio | 0% |
How did GX1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 05:48 |
| End of Day Share Price | 2026/05/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
genXone S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.